While this happened, Ascendiant Capital Markets initiated its Lucid Diagnostics Inc [LUCD] rating to a Buy in a research note published on December 27, 2021; the price target was $16. A number of analysts have revised their coverage, including Needham’s analysts, who began to cover the stock in early November with a ‘”a Buy”‘ rating. Cantor Fitzgerald began covering LUCD with “an Overweight” recommendation on November 08, 2021. BTIG Research started covering the stock on November 08, 2021. It rated LUCD as “a Buy”.
Price Performance Review of LUCD
On Tuesday, Lucid Diagnostics Inc [NASDAQ:LUCD] saw its stock fall -1.60% to $1.23. Over the last five days, the stock has lost -2.38%. Lucid Diagnostics Inc shares have risen nearly 50.24% since the year began. Nevertheless, the stocks have risen 29.47% over the past one year. While a 52-week high of $1.80 was reached on 04/08/25, a 52-week low of $0.68 was recorded on 01/02/25. SMA at 50 days reached $1.3738, while 200 days put it at $1.0151.
Levels Of Support And Resistance For LUCD Stock
The 24-hour chart illustrates a support level at 1.2100, which if violated will result in even more drops to 1.1900. On the upside, there is a resistance level at 1.2500. A further resistance level may holdings at 1.2700. The Relative Strength Index (RSI) on the 14-day chart is 43.59, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.0004, which suggests price will go down in the next trading period. Percent R suggests that price movement has been low at 44.83%. Stochastics %K at 63.79% indicates the stock is a holding.
